Comparative Outcomes of Interventions for Femoropopliteal Chronic Total Occlusion Versus Non-Chronic Total Occlusion Lesions From the Multicenter XLPAD Registry.

Background Endovascular intervention of femoropopliteal chronic total occlusions (CTOs) is technically more complex. However, there is lack of comparative analysis between CTO and non-CTO femoropopliteal interventions. Methods and Results We report procedural details and outcomes of patients treated for femoropopliteal CTO and non-CTO lesions in the XLPAD (Excellence in Peripheral Artery Disease) registry (NCT01904851) between 2006 and 2019. Primary outcomes were procedural success and 1-year major adverse limb events, a composite of all-cause death, target limb revascularization, or major amputation. Analysis included 2895 patients (CTO: n=1516 patients; non-CTO: n=1379 patients) with 3658 lesions (CTO: n=1998 lesions; non-CTO: n=1660 lesions). Conventional balloon angioplasty (20.86% versus 33.48%, P <0.001) or drug-coated balloon angioplasty (1.26% versus 2.93%, P <0.001) were more frequent in the non-CTO group, whereas bare-metal stents (28.09% versus 20.22%, P <0.001) or covered stents (4.08% versus 1.83%, P <0.001) were more frequent in the CTO group. Debulking procedures were more commonly performed in the non-CTO group (41.44% versus 53.13%, P <0.001), despite a similar degree of calcification between the 2 groups. Procedural success was higher in the non-CTO group (90.12% versus 96.79%, P <0.001). Procedural complications were higher in the CTO group (7.21% versus 4.66%, P =0.002), mainly due to excess distal embolization (1.5% versus 0.6%, P =0.015). Adjusted 1-year major adverse limb events were higher in the CTO group (22.47% versus 18.77%, P =0.019), driven mainly by target limb revascularization (19.00% versus 15.34%, P =0.013). Conclusions Procedural success is lower for endovascular treatment of femoropopliteal CTO compared with non-CTO lesions. CTO lesions are associated with higher rates of periprocedural complications and reinterventions after 1 year.